- Home
- COP vs AMGN Comparison
COP vs AMGN Comparison
Compare COP & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COP
- AMGN
- Stock Information
- Founded
- COP 1917
- AMGN 1980
- Country
- COP United States
- AMGN United States
- Employees
- COP N/A
- AMGN N/A
- Industry
- COP Integrated oil Companies
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- COP Energy
- AMGN Health Care
- Exchange
- COP Nasdaq
- AMGN Nasdaq
- Market Cap
- COP 123.0B
- AMGN 141.6B
- IPO Year
- COP N/A
- AMGN N/A
- Fundamental
- Price
- COP $95.07
- AMGN $263.38
- Analyst Decision
- COP Buy
- AMGN Buy
- Analyst Count
- COP 17
- AMGN 22
- Target Price
- COP $136.25
- AMGN $329.05
- AVG Volume (30 Days)
- COP 9.1M
- AMGN 5.2M
- Earning Date
- COP 02-06-2025
- AMGN 02-04-2025
- Dividend Yield
- COP 3.28%
- AMGN 3.62%
- EPS Growth
- COP N/A
- AMGN N/A
- EPS
- COP 8.44
- AMGN 7.83
- Revenue
- COP $56,924,000,000.00
- AMGN $32,534,000,000.00
- Revenue This Year
- COP N/A
- AMGN $20.04
- Revenue Next Year
- COP $9.85
- AMGN $3.41
- P/E Ratio
- COP $11.27
- AMGN $33.62
- Revenue Growth
- COP N/A
- AMGN 21.25
- 52 Week Low
- COP $94.27
- AMGN $253.30
- 52 Week High
- COP $135.18
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- COP 21.78
- AMGN 31.29
- Support Level
- COP $102.40
- AMGN $253.30
- Resistance Level
- COP $105.05
- AMGN $280.00
- Average True Range (ATR)
- COP 2.09
- AMGN 5.95
- MACD
- COP -0.91
- AMGN -0.21
- Stochastic Oscillator
- COP 5.97
- AMGN 35.90
About COP ConocoPhillips
ConocoPhillips is a US-based independent exploration and production firm. In 2023, it produced 1.2 million barrels per day of oil and natural gas liquids and 3.1 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2023 were 6.8 billion barrels of oil equivalent.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.